n CME : Your SA Journal of CPD - Long-acting beta-adrenergic agonists and the smart trial : medifile




Extracted from text ... Medifile MEDIFILE The FDA issued an advisory late in 2005, warning that long-acting ?2-adrenergic agonists (LABAs) may increase the chance of severe asthma exacerbations, which may result in death. An increase in deaths was first ascribed to salmeterol in the Serevent Nationwide Surveillance (SNS) study, conducted by the Glaxo research group in the early 1990s. This study compared the safety of salmeterol and salbutamol in treating asthmatic patients, and the results indicated a small but non-significant excess mortality in the group taking salmeterol and a significant excess of asthma events including deaths in patients with severe asthma on entry. ..


Article metrics loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error